A potent glutamine transporter protein inhibitor, V9032, targets ASCT2, inhibits glutamine uptake and promotes the infiltration of tumor-infiltrating lymphocytes into the tumor core (8, 32). The gene discussed is SLC1A5; the disease is neoplasm.